EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer

Munenori Kawai, Akihisa Fukuda, Munehiro Ikeda, Kei Iimori, Kenta Mizukoshi, Kosuke Iwane, Go Yamakawa, Mayuki Omatsu, Mio Namikawa, Makoto Sono, Tomonori Masuda, Yuichi Fukunaga und 13 weitere

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci177533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Munenori Kawai und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology and. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Pancreatic Neoplasms, Vimentin, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KAKENHI, the Japan Agency for Medical Research and Development, the Project for Cancer Research and Therapeutic Evolution, AMED-PRIME.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in Polybromo 1 ( PBRM1 ), a subunit of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex, are frequently observed in several cancers, including pancreatic ductal adenocarcinoma (PDAC). In this study, we demonstrated that pancreas-specific loss of Pbrm1 in mice harboring Kras mutations and Trp53 deletions accelerated the development of poorly differentiated PDAC, epithelial-mesenchymal transition (EMT), and metastasis, resulting in worsened prognosis. Pbrm1 loss in preexisting PDAC shifted the tumor grade from a well- to a poorly differentiated state and elevated vimentin expression. Pbrm1 -null PDAC exhibited downregulation of apical junction genes and upregulation of EMT pathway genes, including the vimentin and squamous molecular subtype signature genes. Mechanistically, PBRM1 bound to the vimentin gene promoter and directly downregulated its expression. Furthermore, suppression of vimentin in Pbrm1 -null PDAC cells reversed the dedifferentiation phenotype and reduced EMT and metastasis. Consistently, reduced PBRM1 expression correlated with high vimentin expression, poorly differentiated histology, a high recurrence rate, and reduced overall survival in human PDACs. Additionally, PDAC with PBRM1 deletion was associated with the aggressive squamous molecular subtype. Our data established PBRM1 as a tumor suppressor that controls tumor grade and metastasis of PDAC by regulating vimentin expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionPancreatic NeoplasmsVimentinCarcinoma, Pancreatic DuctalTranscription FactorsNuclear ProteinsNeoplasm ProteinsAnimalsMiceHumansNeoplasm MetastasisGene Expression Regulation, NeoplasticDNA-Binding ProteinsCell Line, TumorTumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)Mice, KnockoutNeoplasm Grading

Stichwörter der Autor:innen

CancerEpigeneticsGastroenterologyMouse modelsOncology

Substanzen

VimentinTranscription FactorsNuclear ProteinsVim protein, mouseDNA-Binding ProteinsTrp53 protein, mouseTumor Suppressor Protein p53VIM protein, humanProto-Oncogene Proteins p21(ras)Neoplasm Proteins

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology and.
  • Department of Drug Discovery Medicine, Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Internal Medicine II, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
  • Division of Translational Cancer Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Förderung

  • KAKENHI
  • the Japan Agency for Medical Research and Development, the Project for Cancer Research and Therapeutic Evolution
  • AMED-PRIME
  • the Moonshot Research and Development Program
  • COI-NEXT
  • Takeda Foundation
  • Princess Takamatsu Cancer Research Fund
  • Mitsubishi Foundation

Zitieren

APA

Kawai, M., Fukuda, A., Ikeda, M., Iimori, K., Mizukoshi, K., Iwane, K., Yamakawa, G., Omatsu, M., Namikawa, M., Sono, M., Masuda, T., Fukunaga, Y., Nagao, M., Araki, O., Yoshikawa, T., Ogawa, S., Hiramatsu, Y., Tsuda, M., Maruno, T., …, & Seno, H. (2025). Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci177533

Vancouver

Kawai M, Fukuda A, Ikeda M, Iimori K, Mizukoshi K, Iwane K, et al. Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer. Journal of Clinical Investigation. 2025. doi:10.1172/jci177533

BibTeX
@article{Kawai2025,
  author = {Kawai, Munenori and Fukuda, Akihisa and Ikeda, Munehiro and Iimori, Kei and Mizukoshi, Kenta and Iwane, Kosuke and Yamakawa, Go and Omatsu, Mayuki and Namikawa, Mio and Sono, Makoto and Masuda, Tomonori and Fukunaga, Yuichi and Nagao, Munemasa and Araki, Osamu and Yoshikawa, Takaaki and Ogawa, Satoshi and Hiramatsu, Yukiko and Tsuda, Motoyuki and Maruno, Takahisa and Nakanishi, Yuki and Saur, Dieter and Tsuruyama, Tatsuaki and Masui, Toshihiko and Hatano, Etsuro and Seno, Hiroshi},
  title = {Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci177533}
}
Kostenlos starten →